Alejandro Zaffaroni, a prolific biotech entrepreneur and Silicon Valley legend who played an important role in the development of delivering medication by smoking. He was born in Montevideo, Uruguayan and was the son of a banker. His mother died when he was 13, and his father died shortly before he turned 18. He studied for his bachelor's diploma there, and with inside the closing days of the Second World War he boarded a navy shipment delivered to New York, in which he won a PhD in biochemistry at the University of Rochester. He performed postdoctoral studies under a fellowship from America National Institutes of Health.
The concept turned into supplying drugs quickly through the lungs to the brain in the same manner that cigarettes deliver nicotine. He got the idea by trying to reduce the number of smokers and he knew how fast smoking could affect the body. He experimented and changed the nicotine into medication to send it into the lung to the brain. Most drugs at the time had been administered through simple pills or injections. A record of Dr. Zaffaroni’s career through the Life Sciences Foundation notes that the idea of “drug delivery” was so new."I can't envision anyone in present day biotech history who's been dependable straightforwardly or by implication for additional organizations than Alex," said Peter G. Schultz, an educator at the Scripps Exploration Organization in San Diego, who established two organizations with Dr. Zaffaroni.
Early products no longer promoted well, and Alza almost went bankrupt in the late 1970’s before righting itself. It was a question he asked himself a few years ago, while reading about nicotine addiction. Alza Molecular Delivery Corp, the latest Zaffaroni company, will begin human trials of a migraine medicine inhaled through a flat whistle-like device. Alza now needs a device capable of reproducing the lab's vaporization. Zaffaroni was put in touch with Molecular Delivery in Pleasanton by a former Alza chemist who knew about his concept. Stephen Schneider, the company's founder, created a gadget the size of a small shoebox that heated up pure tetrahydrocannabinol, or THC, the primary element in marijuana. It was created as a nausea reliever or hunger stimulant for people who didn't want to burn plant material. When Alza merged with Molecular Delivery in late 2001, the THC project was a huge datasets. When heated, the medicine vaporizes into an odorless micro-particular mist that swiftly travels through the lungs and into the bloodstream, delivering instant relief. Through various studies, and inventions Alza was gained by Johnson and Johnson for about $12 billion out of 2001.
Alza's human trials may fall short of the earlier animal study's success. However, the business may face difficulties in overcoming anxieties of smoking dangerous substances. The device can't administer all medications; over half of the first 300 Rabinowitz examined were ruled out because they were too weak. But there are enough deserving candidates for Zaffaroni to turn a profit. A record of Dr. Zaffaroni’s career through the Life Sciences Foundation notes that the idea of “drug delivery” was so new. How he figured out his invention from his ordinary life by just reading an article, and how he overcame those company struggles. His effect on biotechnology is immeasurable from his inventions.